StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Nektar Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Nektar Therapeutics's R&D Expenses for the twelve months ending Dec 31, 2025 was $117.33M, down 3.0% year over year. For fiscal 2025 it was $117.33M, down 3.0% from the year before. Over ten years it grew -4.3% a year on average. The highest annual figure on record is $434.57M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$117.33M-3.0%
FY2024Dec 31, 2024$120.91M+5.9%
FY2023Dec 31, 2023$114.16M-47.7%
FY2022Dec 31, 2022$218.32M-45.5%
FY2021Dec 31, 2021$400.27M-2.1%
FY2020Dec 31, 2020$408.68M-6.0%
FY2019Dec 31, 2019$434.57M+8.8%
FY2018Dec 31, 2018$399.54M+48.8%
FY2017Dec 31, 2017$268.46M+31.7%
FY2016Dec 31, 2016$203.80M+11.5%
FY2015Dec 31, 2015$182.79M+23.7%
FY2014Dec 31, 2014$147.73M-22.2%
FY2013Dec 31, 2013$190.01M+27.8%
FY2012Dec 31, 2012$148.68M+17.3%
FY2011Dec 31, 2011$126.77M+17.3%
FY2010Dec 31, 2010$108.07M+13.6%
FY2009Dec 31, 2009$95.11M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$29.71M+3.4%
Q3 FY2025Sep 30, 2025$27.25M-22.2%
Q2 FY2025Jun 30, 2025$29.89M+0.5%
Q1 FY2025Mar 31, 2025$30.48M+11.2%
Q4 FY2024Dec 31, 2024$28.75M-4.0%
Q3 FY2024Sep 30, 2024$35.03M+45.5%
Q2 FY2024Jun 30, 2024$29.72M+0.1%
Q1 FY2024Mar 31, 2024$27.41M-10.0%
Q4 FY2023Dec 31, 2023$29.94M-13.8%
Q3 FY2023Sep 30, 2023$24.07M-28.3%
Q2 FY2023Jun 30, 2023$29.68M-30.6%
Q1 FY2023Mar 31, 2023$30.47M-71.6%
Q4 FY2022Dec 31, 2022$34.74M-65.1%
Q3 FY2022Sep 30, 2022$33.59M-67.6%
Q2 FY2022Jun 30, 2022$42.74M-57.8%
Q1 FY2022Mar 31, 2022$107.25M+12.2%
Q4 FY2021Dec 31, 2021$99.61M-3.0%
Q3 FY2021Sep 30, 2021$103.74M+3.2%
Q2 FY2021Jun 30, 2021$101.31M+5.1%
Q1 FY2021Mar 31, 2021$95.60M-12.3%
Q4 FY2020Dec 31, 2020$102.72M-6.9%
Q3 FY2020Sep 30, 2020$100.53M+1.5%
Q2 FY2020Jun 30, 2020$96.44M-9.6%
Q1 FY2020Mar 31, 2020$108.99M-8.0%
Q4 FY2019Dec 31, 2019$110.37M+1.4%
Q3 FY2019Sep 30, 2019$99.05M-3.7%
Q2 FY2019Jun 30, 2019$106.69M+20.8%
Q1 FY2019Mar 31, 2019$118.46M+19.1%
Q4 FY2018Dec 31, 2018$108.88M+33.7%
Q3 FY2018Sep 30, 2018$102.90M+56.6%
Q2 FY2018Jun 30, 2018$88.33M+46.6%
Q1 FY2018Mar 31, 2018$99.42M+62.8%
Q4 FY2017Dec 31, 2017$81.43M+62.1%
Q3 FY2017Sep 30, 2017$65.71M+26.5%
Q2 FY2017Jun 30, 2017$60.26M+15.1%
Q1 FY2017Mar 31, 2017$61.06M–
Q4 FY2016Dec 31, 2016$50.23M–
Q3 FY2016Sep 30, 2016$51.95M–
Q2 FY2016Jun 30, 2016$52.35M–

More Nektar Therapeutics figures

See a number that looks wrong?